Intratumoral Coadministration of Hyaluronidase Enzyme and Oncolytic Adenoviruses Enhances Virus Potency in Metastatic Tumor Models

Purpose: Evaluate the codelivery of hyaluronidase enzyme with oncolytic adenoviruses to determine whether it improves the spread of the virus throughout tumors, thereby leading to a greater overall antitumor efficacy in tumor models. Experimental Design: The optimal dose of hyaluronidase that provided best transduction efficiency and spread of a green fluorescent protein (GFP)-expressing adenovirus within tumors was combined with oncolytic viruses in tumor models to determine whether the combination treatment results in an improvement of antitumor efficacy. Results: In mice injected with the adenovirus Ad5/35GFP and an optimal dose of hyaluronidase (50 U), a significant increase in the number of GFP-expressing cells was observed when compared with animals injected with virus only (P < 0.0001). When the oncolytic adenoviruses Ad5OV or Ad5/35 OV (OV-5 or OV5T35H) were codelivered with 50 U of hyaluronidase, a significant delay in tumor progression was observed, which translated into a significant increase in the mean survival time of tumor-bearing mice compared with either of the monotherapy-treated groups (P < 0.0001). Furthermore, the mice that received the combination of Ad5/35 OV and hyaluronidase showed the best antitumor efficacy. Importantly, the combination treatment did not increase the metastatic potential of the tumors. Lastly, the increase in virus potency observed in animals injected with both enzyme and virus correlated with enhanced virus spread throughout tumors. Conclusion: Antitumor activity and overall survival of mice bearing highly aggressive tumors are significantly improved by codelivery of oncolytic adenoviruses and hyaluronidase when compared with either of the monotherapy-treated groups, and it may prove to be a potent and novel approach to treating patients with cancer.

[1]  C. Yun,et al.  Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. , 2007, Cancer research.

[2]  M. Götte,et al.  Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. , 2006, Cancer research.

[3]  Hoguen Kim,et al.  Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. , 2006, Journal of the National Cancer Institute.

[4]  M. Simpson,et al.  Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. , 2006, The American journal of pathology.

[5]  J S Patton,et al.  A recombinant human enzyme for enhanced interstitial transport of therapeutics. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[6]  M. Simpson Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. , 2006, The American journal of pathology.

[7]  S. Ganesh,et al.  Enhanced Gene Transfer and Oncolysis of Head and Neck Cancer and Melanoma Cells by Fiber Chimeric Oncolytic Adenoviruses , 2006, Clinical Cancer Research.

[8]  D. Ennist,et al.  CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer , 2006, Clinical Cancer Research.

[9]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[10]  V. Lokeshwar,et al.  HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. , 2005, Cancer research.

[11]  K. Alitalo,et al.  Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. , 2005, Cancer research.

[12]  Y. Ge,et al.  CG0070, a conditionally replicating GM-CSF armed oncolytic adenovirus for the treatment of bladder cancer , 2005 .

[13]  S. Karlsson,et al.  Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells , 2004, The journal of gene medicine.

[14]  Erwin G. Van Meir,et al.  Replicative oncolytic adenoviruses in multimodal cancer regimens. , 2003, Human gene therapy.

[15]  M. Soloway,et al.  Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. , 2003, Cancer research.

[16]  Ying Huang,et al.  An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. , 2003, Cancer research.

[17]  W. Rom,et al.  Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. , 2003, Human gene therapy.

[18]  A. Csoka,et al.  Hyaluronidase reduces human breast cancer xenografts in SCID mice , 2002, International journal of cancer.

[19]  M. Simpson,et al.  Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. , 2002, The American journal of pathology.

[20]  W. Rom,et al.  Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. , 2001, Human gene therapy.

[21]  J. Minna,et al.  Stromal and Epithelial Expression of Tumor Markers Hyaluronic Acid and HYAL1 Hyaluronidase in Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[22]  M. Israel,et al.  Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. , 2001, Cancer research.

[23]  M. Israel,et al.  Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. , 2000, Human gene therapy.

[24]  J. Bergelson,et al.  The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. , 2000, Cancer research.

[25]  N. Rubio,et al.  Metastatic burden in nude mice organs measured using prostate tumor PC‐3 cells expressing the luciferase gene as a quantifiable tumor cell marker , 2000, The Prostate.

[26]  C. de Lange Davies,et al.  Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. , 2000, Anticancer research.

[27]  C. Chauzy,et al.  Human breast‐cancer metastasis formation in a nude‐mouse model: Studies of hyaluronidase, hyaluronan and hyaluronan‐binding sites in metastatic cells , 1999, International journal of cancer.

[28]  Y. Chiang,et al.  A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. , 1999, Human gene therapy.

[29]  A. Sagalowsky,et al.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.

[30]  C. Miller,et al.  Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. , 1998, Cancer Research.

[31]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[32]  J. Willson,et al.  Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Delpech,et al.  Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: Comparison between invasive and non‐invasive areas , 1992, International journal of cancer.